Departments of Oncology, the Third Affiliated Hospital of Soochow University, Changzhou, China.
Front Immunol. 2023 Aug 15;14:1209947. doi: 10.3389/fimmu.2023.1209947. eCollection 2023.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line standard treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. However, resistance to EGFR-TKIs is inevitable. Currently, most studies on the mechanism of EGFR-TKIs resistance mainly focus on the spontaneous resistance phenotype of NSCLC cells. Studies have shown that the tumor microenvironment (TME) also mediates EGFR-TKIs resistance in NSCLC. Tumor-associated macrophages (TAMs), one of the central immune cells in the TME of NSCLC, play an essential role in mediating EGFR-TKIs resistance. This study aims to comprehensively review the current mechanisms underlying TAM-mediated resistance to EGFR-TKIs and discuss the potential efficacy of combining EGFR-TKIs with targeted TAMs therapy. Combining EGFR-TKIs with TAMs targeting may improve the prognosis of NSCLC with EGFR mutation to some extent.
表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）是具有 EGFR 突变的晚期非小细胞肺癌（NSCLC）的一线标准治疗方法。然而，EGFR-TKIs 的耐药性是不可避免的。目前，关于 EGFR-TKIs 耐药机制的大多数研究主要集中在 NSCLC 细胞的自发耐药表型上。研究表明，肿瘤微环境（TME）也介导 NSCLC 中 EGFR-TKIs 的耐药性。肿瘤相关巨噬细胞（TAMs）是 NSCLC TME 中的核心免疫细胞之一，在介导 EGFR-TKIs 耐药性方面发挥着重要作用。本研究旨在全面综述 TAM 介导的 EGFR-TKIs 耐药的现有机制，并讨论将 EGFR-TKIs 与靶向 TAMs 治疗相结合的潜在疗效。将 EGFR-TKIs 与 TAMs 靶向治疗相结合可能在一定程度上改善具有 EGFR 突变的 NSCLC 的预后。
Zotero 插件